Role of perioperative immunotherapy in localized renal cell carcinoma

Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Jasmeet, Patil, Goutham, Geynisman, Daniel M., Ghatalia, Pooja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387776/
https://www.ncbi.nlm.nih.gov/pubmed/37529159
http://dx.doi.org/10.1177/17588359231181497
_version_ 1785081959310950400
author Kaur, Jasmeet
Patil, Goutham
Geynisman, Daniel M.
Ghatalia, Pooja
author_facet Kaur, Jasmeet
Patil, Goutham
Geynisman, Daniel M.
Ghatalia, Pooja
author_sort Kaur, Jasmeet
collection PubMed
description Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.
format Online
Article
Text
id pubmed-10387776
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103877762023-08-01 Role of perioperative immunotherapy in localized renal cell carcinoma Kaur, Jasmeet Patil, Goutham Geynisman, Daniel M. Ghatalia, Pooja Ther Adv Med Oncol Review Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC. SAGE Publications 2023-07-29 /pmc/articles/PMC10387776/ /pubmed/37529159 http://dx.doi.org/10.1177/17588359231181497 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Kaur, Jasmeet
Patil, Goutham
Geynisman, Daniel M.
Ghatalia, Pooja
Role of perioperative immunotherapy in localized renal cell carcinoma
title Role of perioperative immunotherapy in localized renal cell carcinoma
title_full Role of perioperative immunotherapy in localized renal cell carcinoma
title_fullStr Role of perioperative immunotherapy in localized renal cell carcinoma
title_full_unstemmed Role of perioperative immunotherapy in localized renal cell carcinoma
title_short Role of perioperative immunotherapy in localized renal cell carcinoma
title_sort role of perioperative immunotherapy in localized renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387776/
https://www.ncbi.nlm.nih.gov/pubmed/37529159
http://dx.doi.org/10.1177/17588359231181497
work_keys_str_mv AT kaurjasmeet roleofperioperativeimmunotherapyinlocalizedrenalcellcarcinoma
AT patilgoutham roleofperioperativeimmunotherapyinlocalizedrenalcellcarcinoma
AT geynismandanielm roleofperioperativeimmunotherapyinlocalizedrenalcellcarcinoma
AT ghataliapooja roleofperioperativeimmunotherapyinlocalizedrenalcellcarcinoma

Ejemplares similares